MacroGenics (NASDAQ:MGNX) Earns Neutral Rating from HC Wainwright
HC Wainwright reissued their neutral rating on shares of MacroGenics (NASDAQ:MGNX – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $4.00 price objective on the biopharmaceutical company’s stock. A number of other analysts have also weighed in on MGNX. Citigroup reduced their price objective […]
More Stories
Republicans Sue to Prevent Counting of Undated Ballots in Pennsylvania Senate Race
By Sam Dorman Republicans have asked the Pennsylvania Supreme Court to intervene in the state’s Senate race, alleging that several...
Insider Selling: MicroStrategy Incorporated (NASDAQ:MSTR) CAO Sells 752 Shares of Stock
MicroStrategy Incorporated (NASDAQ:MSTR – Get Free Report) CAO Jeanine Montgomery sold 752 shares of the firm’s stock in a transaction...
Head to Head Contrast: Neumora Therapeutics (NMRA) & Its Competitors
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) is one of 295 publicly-traded companies in the “Biological products, except diagnostic” industry,...
Traders Buy High Volume of TC Energy Put Options (NYSE:TRP)
TC Energy Co. (NYSE:TRP – Get Free Report) (TSE:TRP) saw some unusual options trading activity on Wednesday. Stock investors purchased...
Traders Buy High Volume of Call Options on MongoDB (NASDAQ:MDB)
MongoDB, Inc. (NASDAQ:MDB – Get Free Report) saw unusually large options trading on Wednesday. Investors acquired 36,130 call options on...
US Households Must Earn Nearly $108,000 to Afford a Median-Priced Home: Report
By Naveen Athrappully Housing affordability has dropped considerably in major American metros, according to the latest data published by Oxford...